Health span, life extension and longevity company investment opportunities.
Research from the Stanford Center on Longevity concluded that Generation X — people born between 1965 and 1980 — will likely live 20–30 years longer than previous generations. A 45-year-old woman in excellent health has a 20% chance of living to 100; her male equivalent has an 11% chance.
In 2024, Ray Kurzweil predicted in The Singularity is Nearer that longevity escape velocity will arrive in the 2030s — the point at which life expectancy increases more than one year per calendar year for those who take good care of themselves.
Which companies are working to make that happen? Can you invest in them? Should you?
Question: “What’s the easiest way to make a small fortune?”
Answer: “Start with a large one!”
Those who invested in the US S&P Biotech Index (ETF: XBI) in 2021 and 2022 lost 20% and 26% respectively. Gains of 8% and 1% followed in 2023 and 2024. XBI then finished up 35% in 2025, driven by a revival in M&A activity, positive clinical trial results, and increased funding. Over time, however, the S&P 500 index (ETF: SPY) has been a much better investment. XBI remains historically volatile.
Keep Health does not recommend investing in this sector unless you are an expert or getting trusted expert advice. There has been a tremendous amount of money made and lost investing in life sciences and healthcare companies. Emerging healthcare startups are speculative investments — more likely overvalued than undervalued. Warren Buffett’s advice applies well here: be “fearful when others are greedy and greedy when others are fearful.” Following sources like CNN’s Fear and Greed Index and Investor’s Business Daily’s Market Trends can help you gauge when the market is overbought or oversold.
Necessary disclaimer: Keep Health is not an investment advisor and the content of this website is not to be used for making or refraining from investment decisions. The information provided is for general information purposes only. It may not be suitable for your situation. Although Keep Health has made every effort to ensure accuracy, Keep Health makes no representation about accuracy and completeness, and disclaims any liability for loss or damages caused by errors or omissions resulting from accident, negligence, or any other cause.
What’s changed since our last update
Three developments define the longevity investment landscape in 2025–2026, and every investor in this space should understand all three.
ETF investing opportunities
Two ETFs offer exposure to longevity and aging-related industries without requiring bets on individual companies.
+7% in 2024 · +20% in 2025
+180% in 2020 · −50% in 2022 · +23% in 2025
An ETF called OLD, focused on the costs of aging rather than its treatment, retired in 2021.
Venture capital firms focused on healthspan and longevity
Since 2016, more than 225 private anti-aging companies have formed. As Sebastian Brunemeier of Healthspan Capital noted at the 2022 Ending Age-Related Diseases conference, anti-aging investments have gone “from fringe to fashionable.” Capital concentration has since shifted toward companies with human clinical data and disease-first strategies, while pure longevity narrative plays have been repriced downward.
Founded by Sebastian Brunemeier, Michael Chinen, and Nathan Cheng. Their 2025 Longevity Bio report covers the leading private companies in depth. The rolling fund on AngelList lets investors participate in pre-seed to Series A longevity rounds with a minimum of $5,000.
Portfolio companies include Deciduous Therapeutics (immune system activation to eliminate senescent cells), ImmuneAge Bio (bone marrow rejuvenation via hematopoietic stem cells), Matter Bio (reversing age-driven DNA mutations), Renewal Bio (embryogenesis-inspired reprogramming), Shift Bioscience (AI-guided cell reprogramming), and Vincere Bio (deficient mitophagy), among others.
Co-founded by British investor Jim Mellon in 2018 and led by Dr. Greg Bailey (Executive Chairman) and Dr. Richard Marshall (CEO). Juvenescence raised a $76 million Series B-1 tranche in 2025 to fund its AI-enabled therapeutics pipeline. The long-pursued IPO has still not materialized after several years of attempts.
Remaining key portfolio companies:
- LyGenesis — organ regeneration using lymph nodes as bioreactors. Also developing pancreas, kidney, and thymus regeneration. Phase 2a trial completion date August 2027.
- Morphoceuticals — tissue regeneration via bioelectric signaling. New CEO appointed April 2024.
- Serina Therapeutics (NYSE: SER) — Parkinson’s disease treatment. Phase 1B cleared by FDA in Q1 2026, launching in Australia. Juvenescence owns 30%.
- Relation Therapeutics — data science to repurpose existing drugs for new clinical applications. Received $15 million from GSK in November 2024.
- Chrysea Labs — autophagy-targeting nutritional products, including Sprevive high-purity spermidine.
Notable public and private companies
Calico launched in 2013 with at least $3.5 billion in backing from Alphabet and AbbVie, and spent more than a decade producing academic research without clinical results. That changed in 2025 — for better and worse simultaneously. In January 2025, Calico reported that fosigotifator, its lead drug candidate developed with AbbVie, failed to outperform placebo in slowing ALS in a Phase II/III trial. AbbVie terminated the long-running collaboration in November 2025 after five clinical programs together produced no commercial success.
However, Calico has since pivoted meaningfully. In June 2025, the company licensed 9MW3811 — an IL-11 targeting monoclonal antibody from Shanghai-based Mabwell Bioscience — for $25 million upfront and up to $571 million in milestone payments. A 2024 Nature study found that blocking IL-11 extended mouse lifespan by 22–25%, and Mabwell had already completed Phase I trials with a favorable safety profile. Calico also won FDA Fast Track and Orphan Drug designations in 2025 for its treatment for autosomal dominant polycystic kidney disease (ADPKD). Fosigotifator additionally received FDA Breakthrough Therapy Designation for Vanishing White Matter Disease. Calico is not publicly traded.
The broader landscape
The longevity sector now spans multiple investment theses worth distinguishing clearly.
GLP-1 drugs as longevity investments. The drugs making the most money in biotech right now — GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) from Novo Nordisk (NYSE: NVO) — are simultaneously showing early signals of extending healthy life. Longevity investing increasingly means owning companies generating real revenue, not just preclinical science. Novo Nordisk is one of the largest companies in the world by market cap and produces one of the bestselling drugs in history. That is a very different investment profile than Retro or NewLimit.
AI drug discovery. Several of 2025’s largest longevity-adjacent rounds went to AI-enabled drug discovery companies. Insilico Medicine raised $110 million; Isomorphic Labs (a DeepMind spinout) raised $600 million. These companies don’t focus exclusively on aging but apply AI to accelerate drug discovery across diseases that disproportionately affect older people.
M&A as validation. Verve Therapeutics, which developed a PCSK9 gene editing therapy that dramatically lowers cholesterol in a single treatment, was acquired by Eli Lilly for $1 billion in 2025 — the clearest signal that big pharma now takes longevity-adjacent gene therapy seriously enough to pay a premium for it. Big pharma spent more than $65 billion acquiring biotech companies through October 2025, the highest level since 2021.
For ongoing coverage of the investment landscape, Longevity.Technology, Healthspan Capital’s annual report, and the SENS Research Foundation remain the most reliable independent trackers. Keep Health’s broader coverage of the science behind these investments lives in Anti-Aging Companies, Cellular Reprogramming, Reversing Aging, and Preventing Age-Related Diseases.
